Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › RNTX

Rein Therapeutics

RNTX Rare disease Lead: Phase 2 1 Biotech Distilled article ↓ 14 filings & releases ↓ Cash $8.5M (Jun 30, 2026) ↓ 1 verdict ↓ 1 timing quote ↓
Respiratory Peptide

Market cap $53.0M 86.3M shares (10-Q, Aug 12, 2026) × $0.614 close Nov 6, 2026

Most recent annual filing: 2026-03-26

Catalyst timeline

9 trackedQuarter catalyst calendar →
  1. admilparant BMS Ph3 topline2H 2026admilparant BMS Ph3 topline, 2H 2026, material
  2. LTI-03 Ph2 interim4Q 2026LTI-03 Ph2 interim, 4Q 2026, notable
  3. RNTX listing updateFeb 17, 2027RNTX listing update, Feb 17, 2027, routine
  4. Tyvaso nebulized PDUFA dateApr 2027Tyvaso nebulized PDUFA date, Apr 2027, material
  5. TETON-1/-2 United Therapeutics PDUFA dateApr 2027TETON-1/-2 United Therapeutics PDUFA date, Apr 2027, material
  6. ASPIRE Vicore Ph2b toplineMid-2027ASPIRE Vicore Ph2b topline, Mid-2027, material
  7. RNTX legacy warrants corporate updateMay 2027RNTX legacy warrants corporate update, May 2027, routine
  8. MIST Avalyn Ph2b topline2H 2027MIST Avalyn Ph2b topline, 2H 2027, material
  9. LTI-03 topline~1H/2H 2028LTI-03 topline, ~1H/2H 2028, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (1 active programs)

Discontinued (2)

Capital (as filed)

Cash
$8.5M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$35.1M Jun 30, 2026
Long-term investments
$3.0M Jun 30, 2026
Operating cash flow
−$8.6M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$43.6M cash, runway into the first quarter of 2028 per the deep dive of Sep 8, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (1)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (1 call)

Every verdict Biotech Distilled has published on Rein Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-09-09 Watch Rein Therapeutics (RNTX) — Scientific Deep Dive for LTI-03 and Pipeline Products The biology is real and the price is cheap, but the differentiating epithelial-regeneration mechanism has no significant human evidence, disclosure is selectively framed, and the true de-risking event is the full 120-patient RENEW Week-24 FVC dataset in 2028, not the Q4 2026 interim.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (14)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Nov 2, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

13 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)